Last reviewed · How we verify
NCT06030843: TREAT-CRS
The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1
Phase 2, PHASE3 trial testing Empagliflozin 10 MG in Empagliflozin in Cardiorenal Syndrome Type 1 in 200 participants. Currently enrolling.
30 November 2025
Quick facts
| Lead sponsor | Chulalongkorn University |
|---|---|
| Phase | Phase 2, PHASE3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 200 |
| Start date | 1 March 2025 |
| Primary completion | 30 November 2025 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across Thailand |
Drugs / interventions tested
- Empagliflozin 10 MG — full drug profile →
- Placebo
Conditions studied
- Empagliflozin in Cardiorenal Syndrome Type 1 — all drugs for Empagliflozin in Cardiorenal Syndrome Type 1 →
Sponsor
Chulalongkorn University
Who can join
18 and older, any sex, with Empagliflozin in Cardiorenal Syndrome Type 1. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Effects of Empagliflozin compared with placebo in cardiorenal syndrome type 1, evaluated by MAKE30.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06030843
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Empagliflozin 10 MG
Trials testing the same drug.
- NCT03867487 — SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease · Phase 2 · not yet recruiting
- NCT06355310 — Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease · Phase 2 · recruiting
- NCT06706791 — Effect of Empagliflozin on Quality of Life in Chronic Heart Failure Patients With Diabetes Mellitus Type II · Phase 4 · recruiting
- NCT06473844 — Efficacy of SGLT2 Inhibitors in Adults With Sepsis · NA · recruiting
- NCT05879276 — Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left · Phase 3 · recruiting
Other Chulalongkorn University trials
Trials by the same sponsor.
- NCT07458659 — Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed/Refractory Multiple Myel · EARLY_PHASE1 · not yet recruiting
- NCT07346118 — Fluid Balance Guided by Modified Venous Excess Ultrasonography Versus Standard Care in Patients With Acute Kidney Injury · NA · not yet recruiting
- NCT07388862 — Comparison of Treatment Outcome of Pulpotomy With Versus Without Dental Operating Microscope in Carious Mature Permanent · EARLY_PHASE1 · not yet recruiting
- NCT07373977 — Comparison of Postoperative Pain After Pulpotomy Performed With Versus Without Dental Operating Microscope in Carious Ma · EARLY_PHASE1 · not yet recruiting
- NCT07078929 — Clinical Trial of CMD63 Chimeric Antigen Receptor T-cell (CAR T-cell) in Children With Acute Lymphoblastic Leukemia (ALL · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06030843 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chulalongkorn University
- Last refreshed: 7 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06030843.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing